osimertinib + almonertinib + furmonertinib

This is a combination of three third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: osimertinib, almonertinib, and furmonertinib. All three agents are small molecule inhibitors that selectively target mutant forms of EGFR, including the T790M resistance mutation commonly found in non-small cell lung cancer (NSCLC). These drugs irreversibly bind to the ATP-binding site of EGFR, inhibiting downstream signaling pathways involved in tumor cell proliferation and survival. Each drug has demonstrated efficacy as monotherapy for NSCLC with EGFR mutations; their combined use would be experimental and not standard clinical practice. The combination could theoretically provide broader inhibition across various EGFR mutations or resistance mechanisms but may also increase toxicity.

Brand names

Tagrisso (osimertinib)Ameile (almonertinib)Ivesa (furmonertinib)

Other names

aumolertinib + furmonertinib + osimertinib